From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups?


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
11 2021
Historique:
received: 28 07 2021
revised: 29 08 2021
accepted: 30 08 2021
pubmed: 11 9 2021
medline: 7 1 2022
entrez: 10 9 2021
Statut: ppublish

Résumé

We aimed to evaluate if the revised staging according to FIGO-2018 in early-stage cervical cancer correctly predicts the risk for nodal metastases. We reallocated 245 women with early-stage cervical cancer from FIGO-2009 to FIGO-2018 stages using data from a national, prospective cohort study on sentinel lymph node (SLN) mapping. We used univariate and multivariate binary regression models to investigate the association between FIGO-2018 stages, tumor characteristics, and nodal metastases. Stage migration occurred in 54.7% (134/245) (95% CI 48.2-61.0), due to tumor size or depth of invasion (71.6%, 96/134) and nodal metastases (28.4%, 38/134). Imaging preoperatively upstaged 7.3% (18/245); seven had nodal metastatic disease on final pathology. Upstaging occurred in 49.8% (122/245) (95% CI 43.4-56.2%) and downstaging to FIGO-2018 IA stages in 4.9% (12/245) (95% CI 2.6-8.4). The tumor size ranged from 3.0-19.0 mm in women with FIGO-2018 IA tumor characteristics, and none of the 14 women had nodal metastases. In multivariate analysis, risk factors significantly associated with nodal metastases were FIGO-2018 ≥ IB2 (RR 5.01, 95% CI 2.30-10.93, p < 0.001), proportionate depth of invasion >2/3 (RR 1.88, 95% CI 1.05-3.35, p = 0.033), and lymphovascular space invasion (RR 5.56, 95% CI 2.92-10.62, p < 0.001). The FIGO-2018 revised staging system causes stage migration for a large proportion of women with early-stage cervical cancer. Women who were downstaged to FIGO-2018 IA stages did not have nodal metastatic disease. The attention on depth of invasion rather than horizontal dimension seems to correctly reflect the risk of nodal metastases.

Identifiants

pubmed: 34503847
pii: S0090-8258(21)01324-X
doi: 10.1016/j.ygyno.2021.08.026
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

281-288

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest There are no conflicts of interest to disclose.

Auteurs

Sara Elisabeth Sponholtz (SE)

Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark; Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark; OPEN, Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark, Denmark. Electronic address: Sara.Elisabeth.Sponholtz@rsyd.dk.

Ole Mogensen (O)

Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark; Institute of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.

Malene Grubbe Hildebrandt (MG)

Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark; Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark; Center for Innovative Medical Technology (CIMT), Odense University Hospital and University of Southern Denmark, Odense, Denmark.

Doris Schledermann (D)

Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark; Department of Clinical Pathology, Odense University Hospital, Odense, Denmark.

Erik Parner (E)

Deparment of Public Health, Aarhus University, Aarhus, Denmark.

Algirdas Markauskas (A)

Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.

Ligita Paskeviciute Frøding (LP)

Department of Gynecology, Copenhagen University Hospital, Denmark.

Katrine Fuglsang (K)

Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark.

Jorun Holm (J)

Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.

Sarah Marie Bjørnholt (SM)

Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark; Institute of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.

Pernille Tine Jensen (PT)

Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark; Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark; Institute of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH